Lucian Lazar

Suggest Changes
Learn More
PURPOSE The study objective was to compare the overall survival (OS) of patients with unresectable or metastatic hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin (DOX). (More)
  • 1